A double blind comparative study on the efficacy of S 6472, cefaclor in the treatment of bacterial bronchitis

Shinichi Oshima; Yoko Yokoyama; Tsuyoshi Kikuiri; Tadashi Murakami; Hisashi Nishihara; Tatsunori Shimizu; Morikuni Abe; Yoshio Kurihara; Choei Itoh; Keisuke Takeuchi; Osamu Yajima; Mikihiko Tango; Einosuke Odagaki; Yoshiaki Ichishima; Akira Saitoh; Kiyofumi Ishikawa; Akira Suzuki; Mitsuo Asagawa; Mitsunari Nakamura; Mitsuhide Ohmichi; Yomei Hiraga; Kohki Kikuchi; Asako Yamamoto; Ichiroh Nakayama; Masumi Tomisawa; Akio Hirayama; Soichiro Uehara; Yohtaroh Oyama; Kyuichiro Sekine; Tohru Natsuisaka; Takehito Nakabayashi; Takahisa Saitoh; Tetsushi Koroku; Hiroshi Kon; Takashi Nakazato; Toshio Kirisawa; Hiroshi Takagi; Katsuo Suzuki; Mikiya Satoh; Fumio Nagahama; Rensuke Kuroda; Fumiei Kondo; Yoichi Gocho; Koichi Nasuhara; Takashi Takahori; Hiroyuki Tokunaka; Akira Ujiie; Masahide Shinohara; Ikuo Fukuhara; Jutaro Shimomura; Ryohji Ohhashi; Sokichi Onodera; Eiichi Sakai; Tetsuo Shimizu; Nobuhiro Sasaki; Yuji Ikeda; Yoshiro Ishii; Matsumi Tosaka; Hajime Watanabe; Hidetoshi Shibaki; Takehisa Chimoto; Yoshitaka Sugawara; Kazuo Takebe; Katsuhiro Okamoto; Syuichiro Yoshida; Teruo Nakamura; Yoshihiro Kumasaka; Tatsuro Irie; Tadashi Miyazawa; Masashi Yoneda; Naoyoshi Masaki; Toyoichi Tamura; Kohzo Kurahashi; Yuichi Hirai; Hitoshi Yashiro; Norihiko Hirota; Masao Tamura; Takashi Itoh; Shigeki Mori; Fumitoshi Yamauchi; Kiyoshi Omuro; Yutaka Ishikawa; Takashi Tsuruya; Hiroshi Kuramitsu; Kotaro Itakura; Yasuyuki Suzuki; Kazutoshi Gomi; Katsuyoshi Moriya; Nobuhisa Satoh; Mikio Matsui; Norimi Maiya; Masao Satoh; Yoshikatsu Nemoto; Kiyoshi Kawamorita; Noboru Asoh; Tsukasa Yoshida; Hiroyoshi Yaoi; Masaaki Itazawa; Syuji Chiba; Saburo Shindoh; Mamoru Furuta; Kiichi Kaishio; Hidetaka Satoh; Kazuo Satoh; Kiyoshi Konno; Kotaro Oizumi; Masako Sasaki; Akira Watanabe; Seiichi Aonuma; Kikuo Ohnuma; Yushi Nakai; Kohsaku Nagai; Tokuji Honda; Fumio Ariji; Ichiro Yoshida; Kazuo Wakasa; Moriaki Nishina; Ryosuke Saeki; Teruo Hasuike; Izumi Hayashi; Tsugushi Ito; Shigeo Takizawa; Yuzuru Matsumoto; Shigemi Kohsaka; Kenkichi Shikanai

doi:10.11553/antibiotics1968b.39.2726

A double blind comparative study on the efficacy of S 6472, cefaclor in the treatment of bacterial bronchitis

Shinichi Oshima, Yoko Yokoyama, Tsuyoshi Kikuiri, Tadashi Murakami, Hisashi Nishihara, Tatsunori Shimizu, Morikuni Abe, Yoshio Kurihara, Choei Itoh, Keisuke Takeuchi, Osamu Yajima, Mikihiko Tango, Einosuke Odagaki, Yoshiaki Ichishima, Akira Saitoh, Kiyofumi Ishikawa, Akira Suzuki, Mitsuo Asagawa, Mitsunari Nakamura, Mitsuhide OhmichiYomei Hiraga, Kohki Kikuchi, Asako Yamamoto, Ichiroh Nakayama, Masumi Tomisawa, Akio Hirayama, Soichiro Uehara, Yohtaroh Oyama, Kyuichiro Sekine, Tohru Natsuisaka, Takehito Nakabayashi, Takahisa Saitoh, Tetsushi Koroku, Hiroshi Kon, Takashi Nakazato, Toshio Kirisawa, Hiroshi Takagi, Katsuo Suzuki, Mikiya Satoh, Fumio Nagahama, Rensuke Kuroda, Fumiei Kondo, Yoichi Gocho, Koichi Nasuhara, Takashi Takahori, Hiroyuki Tokunaka, Akira Ujiie, Masahide Shinohara, Ikuo Fukuhara, Jutaro Shimomura, Ryohji Ohhashi, Sokichi Onodera, Eiichi Sakai, Tetsuo Shimizu, Nobuhiro Sasaki, Yuji Ikeda, Yoshiro Ishii, Matsumi Tosaka, Hajime Watanabe, Hidetoshi Shibaki, Takehisa Chimoto, Yoshitaka Sugawara, Kazuo Takebe, Katsuhiro Okamoto, Syuichiro Yoshida, Teruo Nakamura, Yoshihiro Kumasaka, Tatsuro Irie, Tadashi Miyazawa, Masashi Yoneda, Naoyoshi Masaki, Toyoichi Tamura, Kohzo Kurahashi, Yuichi Hirai, Hitoshi Yashiro, Norihiko Hirota, Masao Tamura, Takashi Itoh, Shigeki Mori, Fumitoshi Yamauchi, Kiyoshi Omuro, Yutaka Ishikawa, Takashi Tsuruya, Hiroshi Kuramitsu, Kotaro Itakura, Yasuyuki Suzuki, Kazutoshi Gomi, Katsuyoshi Moriya, Nobuhisa Satoh, Mikio Matsui, Norimi Maiya, Masao Satoh, Yoshikatsu Nemoto, Kiyoshi Kawamorita, Noboru Asoh, Tsukasa Yoshida, Hiroyoshi Yaoi, Masaaki Itazawa, Syuji Chiba, Saburo Shindoh, Mamoru Furuta, Kiichi Kaishio, Hidetaka Satoh, Kazuo Satoh, Kiyoshi Konno, Kotaro Oizumi, Masako Sasaki, Akira Watanabe, Seiichi Aonuma, Kikuo Ohnuma, Yushi Nakai, Kohsaku Nagai, Tokuji Honda, Fumio Ariji, Ichiro Yoshida, Kazuo Wakasa, Moriaki Nishina, Ryosuke Saeki, Teruo Hasuike, Izumi Hayashi, Tsugushi Ito, Shigeo Takizawa, Yuzuru Matsumoto, Shigemi Kohsaka, Kenkichi Shikanai

Research output: Contribution to journal › Article › peer-review

Abstract

Clinical efficacy and safety of S 6472 (long active cefaclor (CCL)) and CCL were compared by a double-blind study using 248 patients with bacterial bronchitis. Patients were orally administered with either 375 mg of S 6472 2 times or 250 mg of CCL 3 times daily for 7 days, and the following results were obtained. 1. Clinical efficacy judged by a committee: The efficacy rates on acute bronchitis were 87.2% for S 6472 and 82.6% for CCL, and the efficacy rates on chronic bronchitis were 70.3% for S 6472 and 64.7% for CCL. There was no significant difference between the 2 drugs in clinical efficacy. 2. Clinical efficacy judged by doctors in charge: Results of the clinical efficacy judged by doctors in charge were similar to the efficacy judged by the committee. 3. Bacteriological efficacy judged by the committee: Eradication rate for the S 6472 group was 71.1% (32 of 45 patients) and that for the CCL group was 67.4% (29 of 43 patients). There was no significant difference between the 2 drugs in the bacteriological efficacy. 4. Side effects and abnormal laboratory findings: Side effects were observed in 5 cases (4.2%) in the S 6472 group and in 5 cases (4.0%) in the CCL group. These side effects, however, were not serious, and no remarkable abnomal laboratory values were observed. There was no significant difference between the 2 drugs in the incidence of side effects or abnormal laboratory findings. 5. Clinical utility: When the clinical utility was expressed by the utility rate (very useful and useful), it was 79.5% in the S 6472 group (117 patients) and 76.2% in the CCL group (122 patients) (judged by the committee). When the utility was judged by doctors in charge, it was 73.3% in S 6472 group (120 patients) and 71.4% in CCL group (126 patients). From the above results, it has been concluded that S 6472 taken twice daily is equivalent to CCL in effectiveness on bacterial bronchitis.

Original language	English
Pages (from-to)	2726-2753
Number of pages	28
Journal	The Japanese Journal of Antibiotics
Volume	39
Issue number	10
DOIs	https://doi.org/10.11553/antibiotics1968b.39.2726
Publication status	Published - 1986 Oct
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11553/antibiotics1968b.39.2726

Cite this

Oshima, S., Yokoyama, Y., Kikuiri, T., Murakami, T., Nishihara, H., Shimizu, T., Abe, M., Kurihara, Y., Itoh, C., Takeuchi, K., Yajima, O., Tango, M., Odagaki, E., Ichishima, Y., Saitoh, A., Ishikawa, K., Suzuki, A., Asagawa, M., Nakamura, M., ... Shikanai, K. (1986). A double blind comparative study on the efficacy of S 6472, cefaclor in the treatment of bacterial bronchitis. The Japanese Journal of Antibiotics, 39(10), 2726-2753. https://doi.org/10.11553/antibiotics1968b.39.2726

Oshima, S, Yokoyama, Y, Kikuiri, T, Murakami, T, Nishihara, H, Shimizu, T, Abe, M, Kurihara, Y, Itoh, C, Takeuchi, K, Yajima, O, Tango, M, Odagaki, E, Ichishima, Y, Saitoh, A, Ishikawa, K, Suzuki, A, Asagawa, M, Nakamura, M, Ohmichi, M, Hiraga, Y, Kikuchi, K, Yamamoto, A, Nakayama, I, Tomisawa, M, Hirayama, A, Uehara, S, Oyama, Y, Sekine, K, Natsuisaka, T, Nakabayashi, T, Saitoh, T, Koroku, T, Kon, H, Nakazato, T, Kirisawa, T, Takagi, H, Suzuki, K, Satoh, M, Nagahama, F, Kuroda, R, Kondo, F, Gocho, Y, Nasuhara, K, Takahori, T, Tokunaka, H, Ujiie, A, Shinohara, M, Fukuhara, I, Shimomura, J, Ohhashi, R, Onodera, S, Sakai, E, Shimizu, T, Sasaki, N, Ikeda, Y, Ishii, Y, Tosaka, M, Watanabe, H, Shibaki, H, Chimoto, T, Sugawara, Y, Takebe, K, Okamoto, K, Yoshida, S, Nakamura, T, Kumasaka, Y, Irie, T, Miyazawa, T, Yoneda, M, Masaki, N, Tamura, T, Kurahashi, K, Hirai, Y, Yashiro, H, Hirota, N, Tamura, M, Itoh, T, Mori, S, Yamauchi, F, Omuro, K, Ishikawa, Y, Tsuruya, T, Kuramitsu, H, Itakura, K, Suzuki, Y, Gomi, K, Moriya, K, Satoh, N, Matsui, M, Maiya, N, Satoh, M, Nemoto, Y, Kawamorita, K, Asoh, N, Yoshida, T, Yaoi, H, Itazawa, M, Chiba, S, Shindoh, S, Furuta, M, Kaishio, K, Satoh, H, Satoh, K, Konno, K, Oizumi, K, Sasaki, M, Watanabe, A, Aonuma, S, Ohnuma, K, Nakai, Y, Nagai, K, Honda, T, Ariji, F, Yoshida, I, Wakasa, K, Nishina, M, Saeki, R, Hasuike, T, Hayashi, I, Ito, T, Takizawa, S, Matsumoto, Y, Kohsaka, S & Shikanai, K 1986, 'A double blind comparative study on the efficacy of S 6472, cefaclor in the treatment of bacterial bronchitis', The Japanese Journal of Antibiotics, vol. 39, no. 10, pp. 2726-2753. https://doi.org/10.11553/antibiotics1968b.39.2726

@article{c21b93864656436880194ceae15a7607,

title = "A double blind comparative study on the efficacy of S 6472, cefaclor in the treatment of bacterial bronchitis",

abstract = "Clinical efficacy and safety of S 6472 (long active cefaclor (CCL)) and CCL were compared by a double-blind study using 248 patients with bacterial bronchitis. Patients were orally administered with either 375 mg of S 6472 2 times or 250 mg of CCL 3 times daily for 7 days, and the following results were obtained. 1. Clinical efficacy judged by a committee: The efficacy rates on acute bronchitis were 87.2% for S 6472 and 82.6% for CCL, and the efficacy rates on chronic bronchitis were 70.3% for S 6472 and 64.7% for CCL. There was no significant difference between the 2 drugs in clinical efficacy. 2. Clinical efficacy judged by doctors in charge: Results of the clinical efficacy judged by doctors in charge were similar to the efficacy judged by the committee. 3. Bacteriological efficacy judged by the committee: Eradication rate for the S 6472 group was 71.1% (32 of 45 patients) and that for the CCL group was 67.4% (29 of 43 patients). There was no significant difference between the 2 drugs in the bacteriological efficacy. 4. Side effects and abnormal laboratory findings: Side effects were observed in 5 cases (4.2%) in the S 6472 group and in 5 cases (4.0%) in the CCL group. These side effects, however, were not serious, and no remarkable abnomal laboratory values were observed. There was no significant difference between the 2 drugs in the incidence of side effects or abnormal laboratory findings. 5. Clinical utility: When the clinical utility was expressed by the utility rate (very useful and useful), it was 79.5% in the S 6472 group (117 patients) and 76.2% in the CCL group (122 patients) (judged by the committee). When the utility was judged by doctors in charge, it was 73.3% in S 6472 group (120 patients) and 71.4% in CCL group (126 patients). From the above results, it has been concluded that S 6472 taken twice daily is equivalent to CCL in effectiveness on bacterial bronchitis.",

author = "Shinichi Oshima and Yoko Yokoyama and Tsuyoshi Kikuiri and Tadashi Murakami and Hisashi Nishihara and Tatsunori Shimizu and Morikuni Abe and Yoshio Kurihara and Choei Itoh and Keisuke Takeuchi and Osamu Yajima and Mikihiko Tango and Einosuke Odagaki and Yoshiaki Ichishima and Akira Saitoh and Kiyofumi Ishikawa and Akira Suzuki and Mitsuo Asagawa and Mitsunari Nakamura and Mitsuhide Ohmichi and Yomei Hiraga and Kohki Kikuchi and Asako Yamamoto and Ichiroh Nakayama and Masumi Tomisawa and Akio Hirayama and Soichiro Uehara and Yohtaroh Oyama and Kyuichiro Sekine and Tohru Natsuisaka and Takehito Nakabayashi and Takahisa Saitoh and Tetsushi Koroku and Hiroshi Kon and Takashi Nakazato and Toshio Kirisawa and Hiroshi Takagi and Katsuo Suzuki and Mikiya Satoh and Fumio Nagahama and Rensuke Kuroda and Fumiei Kondo and Yoichi Gocho and Koichi Nasuhara and Takashi Takahori and Hiroyuki Tokunaka and Akira Ujiie and Masahide Shinohara and Ikuo Fukuhara and Jutaro Shimomura and Ryohji Ohhashi and Sokichi Onodera and Eiichi Sakai and Tetsuo Shimizu and Nobuhiro Sasaki and Yuji Ikeda and Yoshiro Ishii and Matsumi Tosaka and Hajime Watanabe and Hidetoshi Shibaki and Takehisa Chimoto and Yoshitaka Sugawara and Kazuo Takebe and Katsuhiro Okamoto and Syuichiro Yoshida and Teruo Nakamura and Yoshihiro Kumasaka and Tatsuro Irie and Tadashi Miyazawa and Masashi Yoneda and Naoyoshi Masaki and Toyoichi Tamura and Kohzo Kurahashi and Yuichi Hirai and Hitoshi Yashiro and Norihiko Hirota and Masao Tamura and Takashi Itoh and Shigeki Mori and Fumitoshi Yamauchi and Kiyoshi Omuro and Yutaka Ishikawa and Takashi Tsuruya and Hiroshi Kuramitsu and Kotaro Itakura and Yasuyuki Suzuki and Kazutoshi Gomi and Katsuyoshi Moriya and Nobuhisa Satoh and Mikio Matsui and Norimi Maiya and Masao Satoh and Yoshikatsu Nemoto and Kiyoshi Kawamorita and Noboru Asoh and Tsukasa Yoshida and Hiroyoshi Yaoi and Masaaki Itazawa and Syuji Chiba and Saburo Shindoh and Mamoru Furuta and Kiichi Kaishio and Hidetaka Satoh and Kazuo Satoh and Kiyoshi Konno and Kotaro Oizumi and Masako Sasaki and Akira Watanabe and Seiichi Aonuma and Kikuo Ohnuma and Yushi Nakai and Kohsaku Nagai and Tokuji Honda and Fumio Ariji and Ichiro Yoshida and Kazuo Wakasa and Moriaki Nishina and Ryosuke Saeki and Teruo Hasuike and Izumi Hayashi and Tsugushi Ito and Shigeo Takizawa and Yuzuru Matsumoto and Shigemi Kohsaka and Kenkichi Shikanai",

year = "1986",

month = oct,

doi = "10.11553/antibiotics1968b.39.2726",

language = "English",

volume = "39",

pages = "2726--2753",

journal = "The Japanese Journal of Antibiotics",

issn = "0368-2781",

number = "10",

}

TY - JOUR

T1 - A double blind comparative study on the efficacy of S 6472, cefaclor in the treatment of bacterial bronchitis

AU - Oshima, Shinichi

AU - Yokoyama, Yoko

AU - Kikuiri, Tsuyoshi

AU - Murakami, Tadashi

AU - Nishihara, Hisashi

AU - Shimizu, Tatsunori

AU - Abe, Morikuni

AU - Kurihara, Yoshio

AU - Itoh, Choei

AU - Takeuchi, Keisuke

AU - Yajima, Osamu

AU - Tango, Mikihiko

AU - Odagaki, Einosuke

AU - Ichishima, Yoshiaki

AU - Saitoh, Akira

AU - Ishikawa, Kiyofumi

AU - Suzuki, Akira

AU - Asagawa, Mitsuo

AU - Nakamura, Mitsunari

AU - Ohmichi, Mitsuhide

AU - Hiraga, Yomei

AU - Kikuchi, Kohki

AU - Yamamoto, Asako

AU - Nakayama, Ichiroh

AU - Tomisawa, Masumi

AU - Hirayama, Akio

AU - Uehara, Soichiro

AU - Oyama, Yohtaroh

AU - Sekine, Kyuichiro

AU - Natsuisaka, Tohru

AU - Nakabayashi, Takehito

AU - Saitoh, Takahisa

AU - Koroku, Tetsushi

AU - Kon, Hiroshi

AU - Nakazato, Takashi

AU - Kirisawa, Toshio

AU - Takagi, Hiroshi

AU - Suzuki, Katsuo

AU - Satoh, Mikiya

AU - Nagahama, Fumio

AU - Kuroda, Rensuke

AU - Kondo, Fumiei

AU - Gocho, Yoichi

AU - Nasuhara, Koichi

AU - Takahori, Takashi

AU - Tokunaka, Hiroyuki

AU - Ujiie, Akira

AU - Shinohara, Masahide

AU - Fukuhara, Ikuo

AU - Shimomura, Jutaro

AU - Ohhashi, Ryohji

AU - Onodera, Sokichi

AU - Sakai, Eiichi

AU - Shimizu, Tetsuo

AU - Sasaki, Nobuhiro

AU - Ikeda, Yuji

AU - Ishii, Yoshiro

AU - Tosaka, Matsumi

AU - Watanabe, Hajime

AU - Shibaki, Hidetoshi

AU - Chimoto, Takehisa

AU - Sugawara, Yoshitaka

AU - Takebe, Kazuo

AU - Okamoto, Katsuhiro

AU - Yoshida, Syuichiro

AU - Nakamura, Teruo

AU - Kumasaka, Yoshihiro

AU - Irie, Tatsuro

AU - Miyazawa, Tadashi

AU - Yoneda, Masashi

AU - Masaki, Naoyoshi

AU - Tamura, Toyoichi

AU - Kurahashi, Kohzo

AU - Hirai, Yuichi

AU - Yashiro, Hitoshi

AU - Hirota, Norihiko

AU - Tamura, Masao

AU - Itoh, Takashi

AU - Mori, Shigeki

AU - Yamauchi, Fumitoshi

AU - Omuro, Kiyoshi

AU - Ishikawa, Yutaka

AU - Tsuruya, Takashi

AU - Kuramitsu, Hiroshi

AU - Itakura, Kotaro

AU - Suzuki, Yasuyuki

AU - Gomi, Kazutoshi

AU - Moriya, Katsuyoshi

AU - Satoh, Nobuhisa

AU - Matsui, Mikio

AU - Maiya, Norimi

AU - Satoh, Masao

AU - Nemoto, Yoshikatsu

AU - Kawamorita, Kiyoshi

AU - Asoh, Noboru

AU - Yoshida, Tsukasa

AU - Yaoi, Hiroyoshi

AU - Itazawa, Masaaki

AU - Chiba, Syuji

AU - Shindoh, Saburo

AU - Furuta, Mamoru

AU - Kaishio, Kiichi

AU - Satoh, Hidetaka

AU - Satoh, Kazuo

AU - Konno, Kiyoshi

AU - Oizumi, Kotaro

AU - Sasaki, Masako

AU - Watanabe, Akira

AU - Aonuma, Seiichi

AU - Ohnuma, Kikuo

AU - Nakai, Yushi

AU - Nagai, Kohsaku

AU - Honda, Tokuji

AU - Ariji, Fumio

AU - Yoshida, Ichiro

AU - Wakasa, Kazuo

AU - Nishina, Moriaki

AU - Saeki, Ryosuke

AU - Hasuike, Teruo

AU - Hayashi, Izumi

AU - Ito, Tsugushi

AU - Takizawa, Shigeo

AU - Matsumoto, Yuzuru

AU - Kohsaka, Shigemi

AU - Shikanai, Kenkichi

PY - 1986/10

Y1 - 1986/10

N2 - Clinical efficacy and safety of S 6472 (long active cefaclor (CCL)) and CCL were compared by a double-blind study using 248 patients with bacterial bronchitis. Patients were orally administered with either 375 mg of S 6472 2 times or 250 mg of CCL 3 times daily for 7 days, and the following results were obtained. 1. Clinical efficacy judged by a committee: The efficacy rates on acute bronchitis were 87.2% for S 6472 and 82.6% for CCL, and the efficacy rates on chronic bronchitis were 70.3% for S 6472 and 64.7% for CCL. There was no significant difference between the 2 drugs in clinical efficacy. 2. Clinical efficacy judged by doctors in charge: Results of the clinical efficacy judged by doctors in charge were similar to the efficacy judged by the committee. 3. Bacteriological efficacy judged by the committee: Eradication rate for the S 6472 group was 71.1% (32 of 45 patients) and that for the CCL group was 67.4% (29 of 43 patients). There was no significant difference between the 2 drugs in the bacteriological efficacy. 4. Side effects and abnormal laboratory findings: Side effects were observed in 5 cases (4.2%) in the S 6472 group and in 5 cases (4.0%) in the CCL group. These side effects, however, were not serious, and no remarkable abnomal laboratory values were observed. There was no significant difference between the 2 drugs in the incidence of side effects or abnormal laboratory findings. 5. Clinical utility: When the clinical utility was expressed by the utility rate (very useful and useful), it was 79.5% in the S 6472 group (117 patients) and 76.2% in the CCL group (122 patients) (judged by the committee). When the utility was judged by doctors in charge, it was 73.3% in S 6472 group (120 patients) and 71.4% in CCL group (126 patients). From the above results, it has been concluded that S 6472 taken twice daily is equivalent to CCL in effectiveness on bacterial bronchitis.

AB - Clinical efficacy and safety of S 6472 (long active cefaclor (CCL)) and CCL were compared by a double-blind study using 248 patients with bacterial bronchitis. Patients were orally administered with either 375 mg of S 6472 2 times or 250 mg of CCL 3 times daily for 7 days, and the following results were obtained. 1. Clinical efficacy judged by a committee: The efficacy rates on acute bronchitis were 87.2% for S 6472 and 82.6% for CCL, and the efficacy rates on chronic bronchitis were 70.3% for S 6472 and 64.7% for CCL. There was no significant difference between the 2 drugs in clinical efficacy. 2. Clinical efficacy judged by doctors in charge: Results of the clinical efficacy judged by doctors in charge were similar to the efficacy judged by the committee. 3. Bacteriological efficacy judged by the committee: Eradication rate for the S 6472 group was 71.1% (32 of 45 patients) and that for the CCL group was 67.4% (29 of 43 patients). There was no significant difference between the 2 drugs in the bacteriological efficacy. 4. Side effects and abnormal laboratory findings: Side effects were observed in 5 cases (4.2%) in the S 6472 group and in 5 cases (4.0%) in the CCL group. These side effects, however, were not serious, and no remarkable abnomal laboratory values were observed. There was no significant difference between the 2 drugs in the incidence of side effects or abnormal laboratory findings. 5. Clinical utility: When the clinical utility was expressed by the utility rate (very useful and useful), it was 79.5% in the S 6472 group (117 patients) and 76.2% in the CCL group (122 patients) (judged by the committee). When the utility was judged by doctors in charge, it was 73.3% in S 6472 group (120 patients) and 71.4% in CCL group (126 patients). From the above results, it has been concluded that S 6472 taken twice daily is equivalent to CCL in effectiveness on bacterial bronchitis.

UR - http://www.scopus.com/inward/record.url?scp=0023025447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023025447&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.39.2726

DO - 10.11553/antibiotics1968b.39.2726

M3 - Article

C2 - 3543432

AN - SCOPUS:0023025447

VL - 39

SP - 2726

EP - 2753

JO - The Japanese Journal of Antibiotics

JF - The Japanese Journal of Antibiotics

SN - 0368-2781

IS - 10

ER -

A double blind comparative study on the efficacy of S 6472, cefaclor in the treatment of bacterial bronchitis

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this